



772

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		Docket Number: <b>10793/70</b>	
Application Number <b>10/611,588</b>	Filing date <b>June 30, 2003</b>	Examiner <b>JONES, Jeevon</b>	Art Unit <b>1644</b>
Invention Title <b>ANTIBODIES AND USES THEREOF</b>		Inventor(s) <b>LEVANON, et al.</b>	

Address to:


Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on: July 11, 2005

By:   
Lawrence P. Casson (Reg. No. 46,606)

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby brings the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The filing of this Information Disclosure Statement and the attached PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
3. A copy of each patent, publication or other information listed on the modified PTO form 1449 are enclosed.
4. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge or credit any over payment to Deposit Account No. 11-0600. A duplicate copy of this communication is enclosed for charging purposes.

Dated: July 11, 2005

By:   
Lawrence P. Casson (Reg. No. 46,606)

KENYON & KENYON  
One Broadway  
New York, N.Y. 10004  
(212) 425-7200 (Telephone)  
(212) 425-5288 (Facsimile)  
CUSTOMER NO. 26646



**SUPPLEMENTAL INFORMATION  
DISCLOSURE  
STATEMENT BY APPLICANT  
PTO - 1449 FORM**

**ATTY. DOCKET NO.**  
10793/70

**SERIAL NO.**  
10/611,588

**APPLICANT**  
LEVANON, et al.

**FILING DATE**  
June 30, 2003

**GROUP**  
1644

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO97/02479	January 23, 1997	PCT				

**OTHER DOCUMENTS**

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Arvieux, et al., Blood, 1999, Vol. 93, pp. 4248-4255
	Austin, et al., Molecular Biology of the Cell, Nov. 2001, Suppl., p62a, abstract No. 338
	Somers, et al., Cell, 2000, Vol. 103, pp. 467-479
	de Kruif, J. et al., "New perspectives on recombinant human antibodies" Immunology Today, Elsevier Publications, Vol. 17 No. 10, pp. 453-455, October 1, 1996
	de Kruif, J. et al, "Rapid Selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library" Proc. Natl. Acad. Sci, Vol. 92, pp. 3938-3942, April 1995
	Hoogenboom, H.R., et al., "Antibody phage display technology and its applications" Immunotechnology Vol. 4, No. 1, pp. 1-20, June 1, 1998
	Hoogenboom, H.R., "Designing and optimizing library selection strategies for generating high-affinity antibodies" Trends in biotechnology, Vol. 15, No. 2, pp. 62-70, February 1, 1997

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	